Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Inquiry points to...

    Inquiry points to maker and lab in fatal French drug trial: reports

    Written by savita thakur thakur Published On 2016-05-23T14:28:17+05:30  |  Updated On 23 May 2016 2:28 PM IST
    Inquiry points to maker and lab in fatal French drug trial: reports

    An official investigation into a clinical drug trial that left one person dead and five others hospitalized in France in January pointed to both the laboratory and the maker for committing errors in the testing process, two dailies said.


    Biotrial, the laboratory in charge of conducting the tests in a private facility in Rennes, Brittany, did not properly inform volunteers and implemented a flawed protocol, France's social affairs inspectorate (IGAS) said in a report, of which Le Monde and Liberation dailies published excerpts on their websites on Sunday.


    IGAS also pointed to Portuguese company Bial, maker of the experimental drug, for delays in informing health authorities, but cleared the National Agency of Drug Safety which it said gave relevant and sufficient information.


    An initial inquiry in February found Biotrial was slow to react when the first patient fell ill.


    IGAS' report goes as far as questioning the merits of the tests and the decision to expose volunteers to the risks of an experimental drug, which are not completely predictable.


    All trials on the drug, which is intended to treat mood and anxiety issues as well as movement coordination disorders linked to neurological issues, have since been suspended.


    French Health Minister Marisol Touraine will present IGAS' findings on Monday and is expected to announce a series of measures to regulate clinical trials.


    Biotrial denounced "the carefully orchestrated leaks" and contested the report's findings in a statement on Sunday evening.


    It accuses IGAS of "non-compliance with the adversarial principle," "non-compliance with the right of persons interviewed" and the absence of details on possible conflicts of interest.


    (Reporting by Sophie Louet; Writing by Sybille de La Hamaide; Editing by Andrea Ricci)

    Andrea RicciBiotrialFrench Health Minister Marisol TouraineIGASNational Agency of Drug SafetySophie LouetSybille de La Hamaide
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok